This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2015
One systematic review, three randomized-controlled trials, and four non-randomized studies were identified regarding high dose stimulants for Attention Deficit Hyperactivity Disorder.
Subject indexing assigned by CRD
Amphetamine; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dexedrine; Dextroamphetamine; Drug Dosage Calculations; Mental Healths; Methylphenidate; Ritalin
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published